Verastem Stock Price, News & Analysis

Verastem, Inc. (Nasdaq: VSTM) announced the immediate departure of Chief Medical Officer Frank Neumann, M.D., Ph.D., who is leaving for another opportunity. CEO Brian Stuglik reassured stakeholders that Neumann's exit will not impact the company's strategic goals or ongoing projects, especially in RAS positive cancers. Verastem remains focused on developing innovative treatments to enhance cancer patient care. The company emphasizes its commitment to addressing unmet medical needs amidst ongoing advancements in its drug pipeline.

Verastem, Inc. (Nasdaq: VSTM) announced the grant of stock options and restricted stock units (RSUs) to five new employees as an inducement for their employment, totaling 86,250 options and 43,125 RSUs, with exercise prices set at $2.20 per share. Additionally, Chief Medical Officer Frank Neumann received 350,000 stock options and 150,000 RSUs, with an exercise price of $2.22. Vesting for these awards occurs over four years, contingent on continued service to the company.

Verastem, Inc. (Nasdaq: VSTM) has appointed Dr. Frank Neumann as Chief Medical Officer, aiming to bolster its clinical and regulatory strategy. With extensive oncology experience, Dr. Neumann will focus on advancing therapies, particularly VS-6766 and defactinib, for challenging KRAS mutant tumors. The company emphasizes the significance of these therapies in addressing unmet patient needs, supported by promising clinical trial results. Verastem’s commitment to developing innovative cancer treatments remains strong, as it navigates the complexities of drug development in the oncology sector.

Verastem, Inc. (Nasdaq:VSTM) announced its participation in the virtual H.C. Wainwright BioConnect 2021 Conference. The company's fireside chat will be available for on-demand listening starting January 11, 2021, at 6:00 a.m. EST. This event emphasizes Verastem's commitment to advancing new cancer treatments. The webcast can be accessed through the 'Media' section of the company’s website under 'Events & Presentations.'

Verastem focuses on developing small molecule drugs targeting critical cancer signaling pathways, including RAF/MEK and FAK inhibition.

Verastem, Inc. (Nasdaq: VSTM) has launched a Phase 2 clinical trial of VS-6766, a RAF/MEK inhibitor, combined with defactinib, a FAK inhibitor, for patients with KRAS mutant non-small cell lung cancer (NSCLC). This trial targets the G12V mutation, which has limited treatment options. The RAMP 202 study aims to determine the optimal regimen and assess efficacy and safety. If successful, it may improve therapeutic outcomes for NSCLC patients. The trial follows Verastem's recent initiation of another Phase 2 study of these compounds in ovarian cancer.

Verastem, Inc. (Nasdaq: VSTM) has initiated a Phase 2 clinical trial for its RAF/MEK inhibitor, VS-6766, and FAK inhibitor, defactinib, targeting patients with recurrent low-grade serous ovarian cancer (LGSOC). The study aims to evaluate the efficacy and safety of VS-6766, both alone and in combination with defactinib. This follows promising early results indicating significant clinical activity in KRAS mutant cancers. The trial is crucial in addressing the unmet needs in treating this tough-to-treat cancer type, which impacts many patients with limited options.

Verastem, a biopharmaceutical company, reported significant financial results for Q3 2020, with total revenue reaching $78.6 million, compared to $9.0 million in Q3 2019. A key highlight was the strategic sale of the COPIKTRA franchise to Secura Bio, valued at up to $311 million, providing cash runway until at least 2024.

Verastem continues its focus on advancing the VS-6766 and defactinib program for KRAS mutant solid tumors, with plans to initiate two Phase 2 clinical trials by year-end 2020.

Verastem, Inc. (Nasdaq: VSTM) has published new clinical data in The Lancet Oncology regarding its drug VS-6766, focusing on its efficacy in treating RAS/RAF-mutant cancers. The study involved 58 patients and showed a tolerable dosing schedule, with an objective response rate of 26.9% in patients with RAS mutations. Important results highlighted that 30% of NSCLC patients had positive responses. The company plans to initiate Phase 2 trials for VS-6766 in low-grade serous ovarian cancer and KRAS-mutant NSCLC by year-end, signaling a strategic move in advanced cancer treatment.

Verastem, Inc. (Nasdaq: VSTM) has announced the grant of stock options for 39,000 shares and restricted stock units (RSUs) for 22,500 shares to five new employees. This grant was made as an inducement for their employment and complies with Nasdaq Listing Rule 5635(c)(4). The options are priced at $1.26 per share, reflecting the closing price on October 1, 2020. Vesting of these awards will occur over four years, with 25% vesting after one year and the remainder vesting quarterly.